We are thrilled to share a groundbreaking update from the MR-Linac Consortium: The Royal Marsden has successfully opened recruitment for DESTINATION 2, enrolling over 15 patients into this pioneering trial!
As the first Hypothesis Testing Program (HTP) phase II/R-IDEAL 2b study, DESTINATION 2 is redefining prostate cancer treatment. Co-designed by Dr Danny Vesprini, Prof Uulke van der Heide, and Dr Alison Tree, the trial explores whether dose de-escalation to healthy prostate tissue can reduce treatment toxicity while maintaining excellent cancer control.
This is one of the world’s first randomised 2-fraction prostate trials, leveraging the Unity MR-Linac’s precision with a 0mm PTV margin—a major step forward in adaptive radiotherapy.
🔬 Trial Design Highlights:
- Patient Population: Men with localised prostate cancer, good urinary function, and MRI-visible tumours.
- Primary Endpoint: Acute genitourinary toxicity.
- Treatment Arms:
- Arm 1 (Uniform Dose): 27 Gy in 2 fractions to the entire prostate ± seminal vesicles.
- Arm 2 (De-escalated Dose): 27 Gy to tumour +4mm margin, 20 Gy to normal prostate tissue ± seminal vesicles.
🌍 Global Collaboration & Early Success
DESTINATION 2 is a federated international trial operating within the MOMENTUM infrastructure, aiming to recruit 200 patients worldwide. Under unified leadership, participating centres maintain operational independence while contributing to a shared research vision.
Early results are promising:
- Excellent patient tolerance and 100% ePROM completion rate.
- Patients are enthusiastic about contributing to research that could transform prostate cancer care.
🏥 More Centres Joining Soon!
With three additional centres preparing to open, the momentum is building. We look forward to expanding this collaboration and continuing to push the boundaries of MR-guided radiotherapy.
Stay tuned for more updates as DESTINATION 2 continues to shape the future of precision oncology!
